VERTEX PHARMACEUTICALS INC / MA Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount of $6.10 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-10-25.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense · last filed 2018-10-25
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, noncontrolling interest income (loss), amount for the quarter ending 2018-09-30 was $100.00K.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, noncontrolling interest income (loss), amount for the quarter ending 2018-06-30 was -$400.00K.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, noncontrolling interest income (loss), amount for the quarter ending 2018-03-31 was $6.40M.
| Period end | Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount 3 month | Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount 6 month | Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount 9 month |
|---|---|---|---|
| 2018-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | -$300.00K derived: sum of 2 quarters · filed 2018-10-25 | $6.10M 10-Q · filed 2018-10-25 |
| 2018-06-30 | -$400.00K 10-Q · filed 2018-07-26 | $6.00M 10-Q · filed 2018-07-26 | |
| 2018-03-31 | $6.40M 10-Q · filed 2018-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |